408 related articles for article (PubMed ID: 18671880)
1. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Yuan WJ; Yasuhara T; Shingo T; Muraoka K; Agari T; Kameda M; Uozumi T; Tajiri N; Morimoto T; Jing M; Baba T; Wang F; Leung H; Matsui T; Miyoshi Y; Date I
BMC Neurosci; 2008 Aug; 9():75. PubMed ID: 18671880
[TBL] [Abstract][Full Text] [Related]
2. Edaravone protects neurons in the rat substantia nigra against 6-hydroxydopamine-induced oxidative stress damage.
Liu X; Shao R; Li M; Yang G
Cell Biochem Biophys; 2014 Nov; 70(2):1247-54. PubMed ID: 24948472
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
5. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
8. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
11. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
12. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
[TBL] [Abstract][Full Text] [Related]
13. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
15. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS
J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534
[TBL] [Abstract][Full Text] [Related]
16. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
17. Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease
Zhou H; Shao M; Yang X; Li C; Cui G; Gao C; Di L; Zhong H; Wang Y; Zhang Z; Lee SM
Oxid Med Cell Longev; 2019; 2019():8169125. PubMed ID: 31827703
[TBL] [Abstract][Full Text] [Related]
18. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
19. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
20. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.
Wang F; Yasuhara T; Shingo T; Kameda M; Tajiri N; Yuan WJ; Kondo A; Kadota T; Baba T; Tayra JT; Kikuchi Y; Miyoshi Y; Date I
BMC Neurosci; 2010 Apr; 11():52. PubMed ID: 20420688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]